www.fdanews.com/articles/75166-private-placement-of-convertible-preferred-shares-for-2-5-million
PRIVATE PLACEMENT OF CONVERTIBLE PREFERRED SHARES FOR $2.5 MILLION
August 9, 2005
InNexus Biotechnology, Inc. (the "Company") has negotiated a private placement with U.S. institutional sources led by SDS Capital Group SPC, Ltd. as a principle investor. The financing will enable the Company's business plan for the continued development of the Company's SuperAntibody and TransMab technologies.
Canada NewsWire Group (http://www.newswire.ca/en/releases/archive/August2005/08/c7909.html)